Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03798626
Title Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

renal cell carcinoma

colorectal cancer

gastroesophageal cancer

Therapies

Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052

Paclitaxel + Ramucirumab + XOMA 052

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052

Cabozantinib + XOMA 052

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.